Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Wendye Robbins Biography and Net Worth

Director of RAPT Therapeutics

Wendye Robbins M.D. serves as Independent Director of the Company. She has served as President and CEO of Blade Therapeutics since August 2016 (and previously held the title of Interim CEO from May 2015 to July 2016). Dr. Robbins has also served as an independent consultant to venture investors in company formation and translational biology. Dr. Robbins has also served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine since 2004. Dr. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine, and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Dr. Robbins received an M.D. from The Medical College of Pennsylvania and a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley. Robbins’ extensive experience in the biopharmaceutical industry, her industry expertise and financial knowledge provide her with the qualifications and skills to serve as a director of our company.

What is Wendye Robbins' net worth?: The estimated net worth of Wendye Robbins is at least $118,455.00 as of March 14th, 2023. Dr. Robbins owns 14,900 shares of RAPT Therapeutics stock worth more than $118,455 as of April 19th. This net worth estimate does not reflect any other investments that Dr. Robbins may own. Learn More about Wendye Robbins' net worth.
How do I contact Wendye Robbins?: The corporate mailing address for Dr. Robbins and other RAPT Therapeutics executives is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. RAPT Therapeutics can also be reached via phone at (650) 489-9000 and via email at [email protected]. Learn More on Wendye Robbins' contact information.
Has Wendye Robbins been buying or selling shares of RAPT Therapeutics?: Wendye Robbins has not been actively trading shares of RAPT Therapeutics in the last ninety days. Most recently, on Tuesday, March 14th, Wendye Robbins bought 2,500 shares of RAPT Therapeutics stock. The stock was acquired at an average cost of $18.99 per share, with a total value of $47,475.00. Following the completion of the transaction, the director now directly owns 14,900 shares of the company's stock, valued at $282,951. Learn More on Wendye Robbins' trading history.
Who are RAPT Therapeutics' active insiders?: RAPT Therapeutics' insider roster includes Dirk Brockstedt (Insider), William Ho (Insider), and Wendye Robbins (Director). Learn More on RAPT Therapeutics' active insiders.
Are insiders buying or selling shares of RAPT Therapeutics?: In the last twelve months, insiders at the sold shares 6 times. They sold a total of 14,898 shares worth more than $276,361.44. The most recent insider tranaction occured on January, 5th when insider Dirk G Brockstedt sold 898 shares worth more than $20,456.44. Insiders at RAPT Therapeutics own 6.6% of the company. Learn More about insider trades at RAPT Therapeutics.
Information on this page was last updated on 1/5/2024.

Wendye Robbins Insider Trading History at RAPT Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2023	Buy	2,500	$18.99	$47,475.00	14,900
5/10/2022	Buy	4,500	$11.24	$50,580.00	13,800
10/18/2021	Buy	500	$30.70	$15,350.00
10/13/2021	Buy	400	$29.69	$11,876.00
8/23/2021	Buy	1,475	$31.39	$46,300.25
8/20/2021	Buy	600	$29.53	$17,718.00
7/7/2021	Buy	1,000	$30.18	$30,180.00	7,400
6/16/2021	Buy	700	$31.54	$22,078.00	6,600
4/13/2021	Buy	700	$19.46	$13,622.00	5,800
4/9/2021	Buy	600	$21.12	$12,672.00	4,826
11/19/2020	Buy	500	$16.08	$8,040.00	5,100
9/28/2020	Buy	500	$28.70	$14,350.00	6,350
9/24/2020	Buy	200	$28.00	$5,600.00	5,750
7/24/2020	Buy	900	$22.47	$20,223.00	5,050
7/1/2020	Buy	2,600	$26.01	$67,626.00	3,550
6/29/2020	Buy	1,600	$25.77	$41,232.00	3,550
11/4/2019	Buy	1,600	$14.49	$23,184.00

Wendye Robbins Buying and Selling Activity at RAPT Therapeutics

RAPT Therapeutics Company Overview

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Today's Range

Now: $7.95

$7.62

$7.96

50 Day Range

MA: $10.65

$6.87

$26.45

2 Week Range

Now: $7.95

$6.86

$27.35

Volume

791,283 shs

Average Volume

1,193,264 shs

Market Capitalization

$276.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47